Header Logo

Connection

Johnny Mahlangu to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Johnny Mahlangu has written about Antibodies, Monoclonal.
Johnny Mahlangu
Connection Strength
0,184
Antibodies, Monoclonal
  1. A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood. 2022 04 28; 139(17):2642-2652.
    View in: PubMed
    Score: 0,184
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.